They pretty much came out and said that with the new rebate being offered for belviq, they will be making much less and said the market was weak (for now). Their other drugs are promising, but far out, and also need money to progress.
I think investors see this as the last straw (the secondary) and are just leaving and taking what they can get until the next catalyst draws near. All, imo.
Market Data 
Markets 
AI
